🚨 EMA Releases New Guideline on the Chemistry of Active Substances (2026): What Pharma Professionals Must Know

⚕️ European Medicines AgencyOFFICIAL RELEASE

🔥 NEW GUIDELINE 2026

Chemistry of Active Substances

ICH Q11 alignment • Quality by Design (QbD) • Advanced CMC framework

📅 Effective: Immediate🎯 API Manufacturers | MA Holders

2026

Active Substance Master File

📄 Guideline EMA/CHMP/98765/2026🏛️ Adopted March 2026Read the Q&A →

Introduction

The pharmaceutical regulatory landscape continues to evolve rapidly, and 2026 marks another significant milestone with the release of a new guideline by the European Medicines Agency (EMA).

Adopted on February 16, 2026, and set to come into effect on September 1, 2026, the “Guideline on the Chemistry of Active Substances” introduces updated expectations for the development, manufacture, and control of active pharmaceutical ingredients (APIs).

For pharmaceutical professionals in Bangladesh and across the globe, this guideline is not just a regulatory document—it is a roadmap for compliance, quality assurance, and global market access.

This article from PharmaJobAid breaks down everything you need to know, from technical requirements to career implications.

Why This EMA Guideline Matters

The active substance (API) is the core of any medicinal product. Regulatory authorities worldwide, including EMA, are strengthening expectations around API quality due to:

Increasing global supply chain complexity
Rising concerns about nitrosamine impurities
Greater scrutiny on data integrity and manufacturing controls
Expansion of international harmonization through International Council for Harmonisation (ICH)

This updated EMA guideline aligns with global regulatory standards while introducing stricter scientific and compliance expectations.

Compliance Timeline: Key Dates

Adoption Date: February 16, 2026
Effective Date: September 1, 2026

👉 This gives pharmaceutical companies approximately 6.5 months to ensure full compliance.

Scope and Applicability

✔ Applies To:

New chemical active substances
Existing active substances used in human medicinal products

❌ Excludes:

Herbal products
Biological and biotechnological products
Radiopharmaceuticals
Radiolabelled products

Regulatory Framework and Legal Basis

The guideline follows the globally accepted Common Technical Document (CTD) structure and aligns with European legislation, particularly:

Directive 2001/83/EC

Key Implication:

Pharmaceutical companies must ensure that Module 3 (Quality)—specifically Section 3.2.S (Active Substance)—meets the updated EMA expectations.

Deep Dive: Active Substance Dossier (CTD Section 3.2.S)

The heart of the guideline lies in defining requirements for the Active Substance Master File (ASMF) or dossier.

1. Manufacture (Section 3.2.S.2)

🔬 Process Description

Companies must provide:

A detailed narrative of the manufacturing process
A schematic flow diagram
Full disclosure of:
- Reagents
- Solvents
- Catalysts

👉 Transparency is now critical—regulators expect full traceability.

🧪 Starting Materials: A Major Focus Area

The guideline introduces stricter requirements:

Starting materials must be:
- Scientifically justified
- Typically separated from the API by multiple synthesis steps
Risk-based evaluation must include:
- Potential for nitrosamine formation
- Source and quality of raw materials

👉 This is especially important for manufacturers in Bangladesh supplying APIs to EU markets.

🔁 Recovery and Reprocessing

EMA allows material recovery—but with strict conditions:

Must be scientifically justified
Must not negatively impact impurity profile
Requires full documentation

Reprocessing must:

Follow Good Manufacturing Practice (GMP)
Be clearly defined and validated

2. Characterisation and Impurities (Section 3.2.S.3)

🧬 Structure Elucidation

To confirm API structure, companies must use:

Nuclear Magnetic Resonance (NMR)
Infrared Spectroscopy (IR)
Mass Spectrometry (MS)

👉 These are standard—but EMA now expects more robust data packages.

⚠️ Impurity Control Strategy

A critical update in 2026:

Strong focus on:
- Mutagenic impurities
- Nitrosamines

Companies must:

Identify potential impurities
Establish acceptable limits
Justify limits using:
- Toxicological data
- Risk assessments

3. Control of Active Substance (Section 3.2.S.4)

📋 Specifications

Minimum required tests:

Description
Identification
Assay
Impurity testing

👉 Specifications must be scientifically justified and aligned with manufacturing capability.

📊 Batch Analysis

Companies must submit:

Data from at least 3 consecutive batches

Purpose:

Demonstrate consistency
Prove process reproducibility

4. Stability (Section 3.2.S.7)

Stability studies must include:

Summary of results
Conclusions
Justification of:
- Re-test period
- Storage conditions

👉 Stability data must reflect real manufacturing and packaging conditions.

Key Updates in the 2026 Revision

1. Nitrosamine Risk Assessment (Major Highlight)

Nitrosamines remain a global regulatory priority.

EMA now requires:

Full risk assessment if:
- Amines are present
- Nitrosating agents are used
Implementation of:
- Risk mitigation strategies
- Control measures

👉 This aligns with global alerts seen in recent years.

2. Starting Material Site Approval

New requirement:

Any change or addition of starting material manufacturing sites requires:
- Formal regulatory approval
- Variation submission

👉 This increases regulatory oversight across the supply chain.

3. Enhanced Impurity Control

Companies must now:

Provide deeper impurity profiling
Include worst-case scenario analysis
Strengthen justification of limits

Impact on Pharmaceutical Industry in Bangladesh

The pharmaceutical sector in Bangladesh is rapidly growing and increasingly export-oriented.

Key Impacts:

🌍 Export Compliance

Companies exporting to Europe must:

Upgrade documentation systems
Strengthen quality control labs
Align with EMA expectations

🏭 Manufacturing Upgrades

Manufacturers must:

Improve process validation
Enhance impurity detection capabilities
Ensure GMP compliance

👨‍🔬 Workforce Demand

This guideline will increase demand for skilled professionals in:

Regulatory Affairs
Quality Assurance (QA)
Quality Control (QC)
Analytical R&D

👉 A great opportunity for job seekers on PharmaJobAid.

Career Opportunities: Why This Matters for You

This regulatory shift creates strong demand for professionals with expertise in:

🔹 Regulatory Affairs

CTD dossier preparation
EMA submission knowledge

🔹 Quality Assurance

GMP compliance
Deviation and CAPA management

🔹 Analytical Chemistry

Impurity profiling
Stability testing

🔹 Production

Process validation
Risk assessment

How PharmaJobAid Can Help

At PharmaJobAid, we are committed to helping you succeed in this evolving regulatory environment.

🚀 Our Services:

CV & Resume Preparation
Interview Preparation
Regulatory Affairs Training
Job Updates in Bangladesh Pharma Industry

👉 Stay ahead of industry changes and build a successful pharma career.

Practical Steps for Companies

To comply with the new EMA guideline, companies should:

✅ Immediate Actions

Conduct gap analysis
Review existing dossiers
Identify high-risk APIs

✅ Mid-Term Actions

Update impurity control strategies
Re-evaluate starting materials
Strengthen analytical methods

✅ Long-Term Strategy

Invest in training
Upgrade manufacturing systems
Implement digital quality systems

Final Thoughts

The 2026 EMA guideline on the chemistry of active substances is more than just a regulatory update—it represents a shift toward greater transparency, scientific rigor, and patient safety.

For pharmaceutical companies, it is a challenge.
For professionals, it is an opportunity.

As global regulations continue to evolve, staying informed and skilled is the key to success.

📢 Stay Connected with PharmaJobAid

👉 Visit: https://pharmajobaid.com/
👉 Follow us for daily pharma job updates, regulatory news, and career tips.